Understanding the Complexity of Diabetes Mellitus and Peripheral Artery Disease

Oct 13, 2025 by ludoplayers7.com 137 views

The Effect of Giving Stem Secretoma Mesenchymal Hypoxia on the Expression of Vascular Endothelial Derived Growth Factor (VEGF), Platelet Derived Growth Factor (PDGF), Thrombospondin-4 (TSP-4) and Angiogenesis in Mice of Diabetes Mellitus with Hindlimb Ischemia

Understanding the Complexity of Diabetes Mellitus and Peripheral Artery Disease

Diabetes mellitus (DM) is a chronic disease that affects millions of people worldwide, causing various complications that can significantly impact the quality of life. One of the most common complications of DM is peripheral artery disease (PAD), characterized by the narrowing of blood vessels in the legs, which can lead to ischemia or lack of blood flow to the tissue. This condition can cause severe pain, limited mobility, and even amputation of the affected limb. In recent years, researchers have been exploring new treatments to overcome PAD, and one of the promising solutions is the use of mesenchymal stem cells (MSCs).

The Potential of Mesenchymal Stem Cells in Overcoming PAD

MSCs have the potential to stimulate angiogenesis, the process of forming new blood vessels, which can increase blood flow to tissues that experience ischemia. This is particularly important in the context of PAD, where the formation of new blood vessels can help to restore blood flow to the affected limb. In this study, we examined the effect of the administration of mesenchymal hypoxia (HMSCS) stem cell secretions on gene expression of vascular endothelial growth factors (VEGF), platelet derivative growth factors (PDGF), thrombospondin-4 (TSP-4), and angiogenesis levels in diabetes mellitus rats (DM) with hindlimb ischemia (HLI).

Research Methods and Interesting Results

This study used 24 wistar rats induced by DM with streptozotocin and HLI through left femoral artery ligation. The rats were then divided into four groups: Sham groups, control groups, HMSCS groups dose 200 μl (P1), and HMSCS groups dose 400 μL (P2). HMSCS used is obtained from the cord of the rat and cultured in hypoxia for 24 hours. VEGF, PDGF, and TSP-4 genes were analyzed with RT-PCR on the 14th day after giving HMSCS. Expressions of CD31, α-SMA, and collagen are analyzed using immunohistochemicals and mass staining of Masson's Thricrome.

The results showed that the administration of HMSCS doses of 400 μl significantly increases the expression of the TSP-4 gene, but has no significant effect on the expression of VEGF and PDGF genes. HMSCS dose of 400 μl also significantly increases CD31 expression, which indicates an increase in angiogenesis. The expression of α-SMA and collagen in the HMSCS group is lower than the control group.

Implications and Future Angiogenesis Therapy

The results of this study indicate that HMSCS has the potential to become a new therapy to overcome the ischemia of Motion Motion in Patients with DM. Increased expression of TSP-4 and CD31 shows that HMSCs can stimulate angiogenesis and increase blood flow to tissues that are experiencing ischemia. However, further research needs to be done to examine the mechanism of work of HMSCS in more detail and to determine the optimal dose and long-term effects.

The Potential of HMSCS in Overcoming PAD

The development of angiogenesis therapy with HMSCS offers new hope for people with DM with HLI. Although still in the research stage, the potential for HMSCS to improve blood flow and prevent the amputation of limbs is very promising. This study provides valuable insights into the potential of HMSCS in overcoming PAD and highlights the need for further research to fully understand its mechanisms and potential applications.

Conclusion

In conclusion, this study demonstrates the potential of HMSCS in stimulating angiogenesis and increasing blood flow to tissues that experience ischemia. The results of this study provide valuable insights into the potential of HMSCS as a new therapy for overcoming PAD and highlight the need for further research to fully understand its mechanisms and potential applications. As researchers continue to explore the potential of HMSCS, we may be one step closer to developing new treatments for PAD and improving the quality of life for people with DM.

Future Directions

Future studies should focus on examining the mechanism of work of HMSCS in more detail and determining the optimal dose and long-term effects. Additionally, further research is needed to explore the potential of HMSCS in other conditions, such as cardiovascular disease and cancer. By continuing to explore the potential of HMSCS, we may be able to develop new treatments that can improve the quality of life for people with DM and other conditions.

Limitations

This study has several limitations, including the small sample size and the use of a specific animal model. Additionally, the study only examined the effect of HMSCS on gene expression and angiogenesis, and did not examine the potential effects on other biological processes. Future studies should aim to address these limitations and provide a more comprehensive understanding of the potential of HMSCS.

Conclusion

In conclusion, this study provides valuable insights into the potential of HMSCS in overcoming PAD and highlights the need for further research to fully understand its mechanisms and potential applications. As researchers continue to explore the potential of HMSCS, we may be one step closer to developing new treatments for PAD and improving the quality of life for people with DM.
Q&A: The Effect of Giving Stem Secretoma Mesenchymal Hypoxia on the Expression of Vascular Endothelial Derived Growth Factor (VEGF), Platelet Derived Growth Factor (PDGF), Thrombospondin-4 (TSP-4) and Angiogenesis in Mice of Diabetes Mellitus with Hindlimb Ischemia

Q: What is the main goal of this study?

A: The main goal of this study is to examine the effect of the administration of mesenchymal hypoxia (HMSCS) stem cell secretions on gene expression of vascular endothelial growth factors (VEGF), platelet derivative growth factors (PDGF), thrombospondin-4 (TSP-4), and angiogenesis levels in diabetes mellitus rats (DM) with hindlimb ischemia (HLI).

Q: What is the significance of this study?

A: This study is significant because it provides valuable insights into the potential of HMSCS in overcoming peripheral artery disease (PAD) and improving blood flow to tissues that experience ischemia. PAD is a common complication of diabetes mellitus (DM) that can lead to severe pain, limited mobility, and even amputation of the affected limb.

Q: What are the potential benefits of HMSCS in overcoming PAD?

A: The potential benefits of HMSCS in overcoming PAD include the stimulation of angiogenesis, the process of forming new blood vessels, which can increase blood flow to tissues that experience ischemia. This can help to restore blood flow to the affected limb and improve the quality of life for people with DM.

Q: What are the limitations of this study?

A: The limitations of this study include the small sample size and the use of a specific animal model. Additionally, the study only examined the effect of HMSCS on gene expression and angiogenesis, and did not examine the potential effects on other biological processes.

Q: What are the future directions for this research?

A: Future studies should focus on examining the mechanism of work of HMSCS in more detail and determining the optimal dose and long-term effects. Additionally, further research is needed to explore the potential of HMSCS in other conditions, such as cardiovascular disease and cancer.

Q: What are the potential applications of HMSCS in overcoming PAD?

A: The potential applications of HMSCS in overcoming PAD include the development of new treatments that can improve the quality of life for people with DM. This could include the use of HMSCS as a therapy to stimulate angiogenesis and increase blood flow to tissues that experience ischemia.

Q: What are the potential risks and side effects of HMSCS?

A: The potential risks and side effects of HMSCS are not well understood and require further research. However, it is possible that HMSCS could cause adverse effects, such as inflammation or immune system reactions.

Q: How can HMSCS be administered?

A: HMSCS can be administered through various routes, including intravenous injection, intramuscular injection, or topical application. The optimal route of administration and dosage require further research.

Q: What are the potential benefits of HMSCS in other conditions?

A: The potential benefits of HMSCS in other conditions, such as cardiovascular disease and cancer, are not well understood and require further research. However, it is possible that HMSCS could have beneficial effects in these conditions, such as stimulating angiogenesis and improving blood flow to tissues.

Q: What are the next steps for this research?

A: The next steps for this research include further studies to examine the mechanism of work of HMSCS, determine the optimal dose and long-term effects, and explore the potential of HMSCS in other conditions. Additionally, clinical trials are needed to evaluate the safety and efficacy of HMSCS in humans.